Endocrine Society's Statement Emphasizes Health Improvements in Obesity Treatment
A new Scientific Statement released by the Endocrine Society emphasizes that obesity treatment should prioritize improvements in overall health rather than focusing exclusively on weight loss. This perspective is crucial as obesity is recognized as a complex, chronic disease influenced by various factors including biology, genetics, metabolism, and environmental conditions. Over 40% of American adults are affected by obesity, which incurs significant medical costs exceeding $173 billion annually in the U.S. due to related health issues.
Dr. Daniel J. Drucker, M.D., from Mount Sinai Hospital in Toronto and the lead author of the Scientific Statement, stated, "This Statement highlights major advances in obesity science and outlines areas of research needed to improve our understanding of the disease, optimize treatment, personalize care, and improve long-term health outcomes for people living with obesity." The introduction of effective obesity medications has transformed treatment options, but critical questions remain regarding their long-term use, individualized treatment strategies, potential side effects, and the best methods for measuring treatment outcomes.
The statement also discusses the role of GLP-1 based therapies, such as semaglutide and tirzepatide, which have not only revolutionized obesity treatment but have also shown promise in managing comorbidities like heart disease, sleep apnea, and liver disease. These medications are currently being explored for their efficacy in treating other conditions, including cancer and substance use disorders.
Untreated obesity can lead to significant declines in metabolic and mental health, affecting individuals' ability to perform daily physical tasks. However, the use of GLP-1 medications comes with safety considerations, including the potential for rapid weight loss and the uncertainty surrounding long-term risks and outcomes. Research indicates that obesity requires ongoing treatment; individuals who discontinue therapy after reaching their weight goals often regain lost weight and experience a deterioration in health metrics such as blood pressure and blood sugar levels. Studies suggest that maintaining weight loss is possible through transitioning to lower doses or different medications post-initial treatment.
The Scientific Statement outlines key questions and priorities for future research in obesity treatment. Dr. Drucker emphasized the need for larger, longer, and more diverse studies, as well as the incorporation of real-world data to better understand treatment outcomes.
The Endocrine Society's Scientific Statements aim to explore the scientific basis of hormone-related conditions and diseases, applying this knowledge in practice while identifying areas that require further research. This particular statement, titled "Obesity Science, Research Gaps, and Opportunities in the New Era of Obesity Medicines," was published in the Society's journal, Endocrine Reviews, and is part of the Society’s broader initiative to advance obesity research and care.




